EU publishes much-awaited revision to its guidance on borderline products
This article was originally published in SRA
Executive Summary
The European Commission has updated its guidance on borderline products, offering further clarity on cases where it is not clear from the outset whether a given product is a medical device, an in vitro diagnostic or a medicinal product1,2.